**In vivo early diagnosis of gastric dysplasia using narrow-band image-guided Raman endoscopy**

Zhiwei Huang  
Mads Sylvest Bergholt  
Wei Zheng  
Kan Lin  
National University of Singapore  
Department of Bioengineering  
Faculty of Engineering  
Optical Bioimaging Laboratory  
Singapore 117576

Khek Yu Ho  
National University of Singapore and  
National University Hospital  
Yong Loo Lin School of Medicine  
Department of Pathology  
Singapore 119074

Ming Teh  
National University of Singapore and  
National University Hospital  
Yong Loo Lin School of Medicine  
Department of Medicine  
Singapore 119260

Khay Guan Yeoh  
National University of Singapore and  
National University Hospital  
Yong Loo Lin School of Medicine  
Department of Medicine  
Singapore 119260

**Abstract.** We first report on the implementation of a novel narrow-band image-guided Raman endoscopy technique for in vivo diagnosis of gastric dysplasia. High-quality in vivo Raman spectra can be acquired from normal and dysplastic gastric mucosal tissue within 0.5 sec under narrow-band image (NBI) guidance at gastroscopy. Significant differences are observed in in vivo Raman spectra between normal (n=54) and dysplastic (n=18) gastric tissue from 30 gastric patients, particularly in the spectral ranges of 825 to 950, 1000 to 1100, 1250 to 1500, and 1600 to 1800 cm⁻¹, which primarily contain signals related to proteins, nucleic acids, and lipids. The multivariate analysis [i.e., principal components analysis (PCA) and linear discriminant analysis (LDA)], together with the leave-one tissue site-out, cross validation on in vivo gastric Raman spectra yields a diagnostic sensitivity of 94.4% (17/18) and specificity of 96.3% (52/54) for distinction of gastric dysplastic tissue. This study suggests that narrowband image-guided Raman endoscopy associated with PCA-LDA diagnostic algorithms has potential for the noninvasive, in vivo early diagnosis and detection of gastric precancer during clinical gastroscopic examination.© 2010 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3420115]

Keywords: gastric dysplasia; in vivo diagnosis; Raman endoscopy; narrow-band imaging; gastroscopy; precancer.

Paper 10001LRR received Jan. 4, 2010; revised manuscript received Mar. 27, 2010; accepted for publication Apr. 1, 2010; published online Jun. 1, 2010.

1 Introduction

Gastric cancer is the second leading cause of cancer-associated death, accounting for approximately 600,000 annual deaths worldwide.¹ Early diagnosis and localization with appropriate curative treatments (e.g., endoscopic submucosal dissection and gastrectomy) is critical to decreasing mortality.² However, identification of early cancer and precancer can be difficult, as conventional white-light reflectance (WLR) endoscopy heavily relies on visual identification of morphological tissue changes. Thus, subtle changes of gastric precancer (i.e., dysplasia) and early cancer may not be apparent, limiting diagnostic accuracy. Positive endoscopic biopsy is the standard criterion for gastric precancer and cancer diagnosis, but it is invasive and impractical for screening high-risk patients who may have multiple suspicious lesions.³,⁴

Very recently, narrow-band imaging (NBI) that enhances visualization of irregular mucosal and vascular patterns has shown promise for improving in vivo diagnosis of intraepithelial neoplastic lesions in gastric tissue.⁵ Although the NBI technique provides good detection sensitivities, this wide-field endoscopic imaging modality still suffers from moderate diagnostic specificity due to the deficiency of revealing specific biochemical information of tissue. Hence, a noninvasive optical diagnostic technique providing a direct assessment of biochemical information of suspicious lesions in vivo will represent a significant advance in endoscopic detection of precancer and early cancer in gastric tissue.

In the past decade, Raman spectroscopy, which measures inelastic light scattering processes and is capable of providing spectroscopic fingerprints of specific molecular structures and compositions of biological tissues, has been comprehensively investigated for precancer and cancer diagnosis and evaluation in a number of organs, including the stomach.⁶-¹⁴ These investigations show that specific spectral features of Raman spectra could be used to correlate with the molecular and structural changes of tissue associated with neoplastic trans-
formation. Diagnostic sensitivities of ~85 to 95% and specificities of ~90 to 98% have been reported for differentiation between normal and pathological (e.g., dysplasia, adenocarcinoma) gastric tissues in vitro using Raman spectroscopic technique. However, to date, in vivo Raman studies for early diagnosis of gastric precancer and cancer have not been reported. In vivo Raman endoscopic applications have been limited not only by the difficulty of capturing inherently weak tissue Raman signals, but also by the relatively high speed of spectral acquisitions required in clinical settings. The fabrication of a millimeter-scaled or even smaller flexible fiber optic Raman probe with abilities of efficient fiber fluorescence/Raman background rejections while having high tissue Raman signal collection efficiency renders another technical challenge for clinical Raman endoscopic examinations. Very recently, we have successfully developed a high throughput Raman endoscopy system integrated with trimodal wide-field endoscopic imaging for rapid in vivo gastric tissue Raman measurements at gastroscopy. With the unique image-guided Raman endoscopy technique developed, we aim, in this work, to evaluate the clinical utility of Raman spectroscopy for in vivo diagnosis and detection of gastric dysplasia during clinical gastrointestinal examination.

2 Materials and Methods

The Raman endoscopy system developed consists of a spectrum-stabilized 785-nm diode laser (maximum output: 300 mW, B&W TEK Incorporated, Newark, Delaware), a transmissive imaging spectrograph (Holospec f/1.8, Kaiser Optical Systems, Ann Arbor, Michigan), a liquid nitrogen-cooled, near-infrared (NIR)-optimized, back-illuminated deep depletion charge-coupled device (CCD) camera (Spec-10: 400BR/LN, Princeton Instruments, Trenton, New Jersey), and a specially designed Raman endoscopic probe for both laser light delivery and in vivo tissue Raman signal collection. The 1.8-mm fiber optic Raman endoscopic probe, which can fit into the biopsy channel of medical endoscopes, consists of 32 Raman collection fibers (core diameter of 200 μm) surrounding the central laser light delivery fiber (core diameter of 200 μm), with two stages of optical filtering incorporated at the proximal and distal ends of the probe for maximizing the collection of tissue Raman signals while reducing the interference of Rayleigh scattered light, fiber fluorescence, and silica Raman signals. A personal computer controls the system using a custom-designed software that triggers real-time data acquisition and online data analysis (e.g., CCD dark-noise subtraction, wavelength calibration, system spectral response calibration, signal saturation detection, cosmic ray rejection, tissue autofluorescence background subtraction, etc.). The system acquires in vivo tissue Raman spectra in the wave number range of 800 to 1800 cm⁻¹, and the spectral resolution of the system is 9 cm⁻¹. Each spectrum was acquired within 0.5 sec using the 785-nm laser light irradiance of 1.5 W/cm², which is less than the American National Standards Institute (ANSI) maximum permissible skin exposure limit set out for a 785-nm laser beam. Our further calculations based on the finite difference thermal model and the optical properties of stomach tissue indicate that even without consideration of other cooling effects (e.g., perfusion and evaporation in tissue), the maximum tissue temperature rise is only about 0.15 °C after 1 min of 785-nm laser radiation with an incident power of 30 mW on a tissue spot size of 200 μm during tissue Raman measurements. This temperature rise estimated is far below the level to generate cytotoxicity in tissue and cells, suggesting that the laser power density used in this study is safe for in vivo tissue Raman measurements. Note that the raw spectra acquired from in vivo gastric tissue represent a combination of intense tissue autofluorescence, weak tissue Raman scattering signals, and noise. These raw spectra are preprocessed by a first-order Savitsky–Golay filter (window width of 3 pixels, corresponding to the system spectral resolution) to reduce noise. A fifth-order polynomial is found to be optimal for fitting the broad autofluorescence background in the noise-smoothed spectrum, and this polynomial is then subtracted from the raw spectrum to yield the tissue Raman spectrum alone. Each background-subtracted Raman spectrum is also normalized to the integrated area under the curve from 800 to 1800 cm⁻¹, enabling better comparison of the spectral shapes and relative peak intensities among different gastric tissues. All of the spectra preprocessing is completed online and the Raman spectrum can be displayed in real time during clinical Raman measurements at gastroscopy. The trimodal endoscopy imaging system primarily comprises a 300-W dedicated short-arc xenon light source, a gastrointestinal (GI) video-endoscopy (GIF-FQ260Z, Olympus), and a video system processor (CV-260SL, Olympus) for white-light reflectance (WLR) imaging, autofluorescence imaging (AFI), and narrow-band imaging (NBI) during gastrointestinal examination. Both the wide-field endoscopic image (WLR/NBI/AFI) and the point-wise in vivo Raman spectra of the tissue image can be simultaneously acquired, stored, and displayed in real time on a color video monitor and computer screen, respectively.

In this work, all patients signed an informed consent permitting the in vivo Raman endoscopic measurements of gastric tissue in the Endoscopy Centre at the National University Hospital (NUH), Singapore. This study was approved by the Institutional Review Board (IRB) of the National Healthcare Group (NHG) of Singapore. We have acquired in vivo Raman spectra [Fig. 1(a)] of 72 gastric mucosal tissue sites in 30 gastric patients (16 men and 14 women, with a median age of 67) under the guidance of wide-field endoscopic imaging [e.g., NBI and WLR imaging in Fig. 1(b)] during gastrointestinal examination. The Raman endoscopic probe was placed in gentle contact with the gastric mucosa surface, and the positioning against the tissue sites was verified on the endoscopy monitor by the endoscopists in charge during gastrointestinal examinations. Immediately after all Raman acquisitions, the biopsy samples were taken from the tissue sites measured (with suction markings) and fixed in 10% formalin solution for histopathological examinations by a senior gastrointestinal pathologist. For the assessment of diagnostic sensitivity and specificity of Raman endoscopy for gastric tissue classification, histopathological results served as the golden standard.

3 Results and Discussion

Figure 1(a) shows the in vivo mean Raman spectra ± 1 standard deviations (SD) and the corresponding Raman difference spectrum of normal (n=54) and dysplastic (n=18) gastric tissue. The representative NBI and WLR image of dysplastic
gastric tissue acquired under Raman endoscopic measurements are shown in Fig. 1. All in vivo tissue Raman spectra are acquired within 0.1 to 0.5 sec (depending on the autofluorescence background level of different gastric tissues) with the 785-nm light irradiance power of 1.5 W/cm². Prominent Raman bands are observed in both normal and dysplastic gastric tissue at the following peak positions with tentative biochemical assignments:4–7,9–14 875 cm⁻¹ [v(C≡C) hydroxyproline], 1004 cm⁻¹ [v(C–C) ring breathing of phenylalanine], 1078 cm⁻¹ [v(OC) or v(CC) of phospholipids], 1265 cm⁻¹ [amide III v(CN) and δ(NH) of proteins], 1302 cm⁻¹ (CH₂CH₂ twisting of proteins and nucleic acids), 1450 cm⁻¹ [δ(CH₂) of proteins and lipids], 1655 cm⁻¹ [amide I v(C=O) of proteins], and 1745 cm⁻¹ [v(C=O) of phospholipids]. The difference spectrum [Fig. 1(a)] reveals the changes of relative percentages of distinctive biomolecules in dysplastic tissue, particularly in the spectral ranges of 825 to 950, 1000 to 1100, 1250 to 1500, and 1600 to 1800 cm⁻¹, which contain signals related to proteins, nucleic acids, and lipids, respectively. Dysplasia tissues show lower intensities at 875, 1004, 1078, 1210, and 1745 cm⁻¹, while higher intensities at 1265, 1302, 1450, and 1655 cm⁻¹, compared with normal tissue. This indicates that there is an increase or decrease in the percentage of a certain type of biomolecules relative to the total Raman-active constituents in gastric tissue associated with dysplastic transformation. More specifically, the decrease in Raman signals at 875 cm⁻¹ (hydroxyproline of collagen) may reflect cytoplasmic mucin depletion and the elevated concentration of metalloproteinase that cleaves collagen in the stroma layer of gastric dysplasia tissue.13,14,22,23 In addition, the thickening of the epithelium associated with dysplastic progression can attenuate the excitation laser power and also obscure the collagen Raman emission from the deep basal membrane,24 thereby resulting in an overall decrease of Raman intensity at 875 cm⁻¹ from dysplasia tissue. The increase of Raman signals attributed to proteins (e.g., 1265, 1302, 1450, and 1655 cm⁻¹) in gastric dysplasia may be associated with an increase in the metabolic activities (e.g., increased mitotic activities that include enzymes, hormones, etc.) as well as the increased hyperchromatism and the nucleic acids-to-cytoplasm ratio of dysplastic cells.23,24 The decrease in Raman signals in the region 1745 cm⁻¹ suggests a reduction of phospholipids in dysplastic tissue that also has been found in other epithelial tissues with malignancies.5,10 Further, there are also obvious changes of Raman peak shifts and bandwidths in the spectral ranges of 1200 to 1500 cm⁻¹ and 1600 to 1800 cm⁻¹, which are related to the amide III and amide I of proteins, CH₂CH₂ twisting of proteins/nucleic acids, and C=O stretching of phospholipids for dysplasia. The current results of in vivo gastric tissue Raman spectra are also similar to our previous observations of in vitro gastric tissue Raman spectra.12–14 Therefore, the distinctive differences in in vivo Raman spectra between normal and dysplastic tissue confirm the potential role of Raman endoscopy for in vivo gastric precancer diagnosis at the molecular level.

We have employed the multivariate statistical technique [i.e., principal components analysis (PCA) and linear discriminant analysis (LDA)] by utilizing the entire Raman spectra to determine the most diagnostically significant Raman features for gastric tissue classification. The unpaired, two-sided Student’s t-test on the obtained principal components (PCs) shows that the three PCs (PC1, PC2, and PC4) (Fig. 2) accounting for ~70.5% of the total variance contain the most diagnostically significant Raman features (p<0.05) for discriminating dysplasia from normal gastric tissue. The first PC accounts for the largest variance (~52.6% of the total variance), whereas the successive PCs describe the spectral features that contribute progressively smaller variances (e.g., PC2 ~ 13.2%, PC4 ~ 4.7%). Some PC features, such as the peaks, troughs, and spectral shapes in Fig. 2, are similar to those of tissue Raman spectra (Fig. 1).

All three significant PCs were loaded into the LDA model to develop effective diagnostic algorithms for gastric tissue diagnosis. Figure 3 shows the classification results of in vivo
Raman spectra of normal and precancer gastric tissue using PCA-LDA together with the leave-one tissue site-out, cross-validation method. The separate line yields a diagnostic sensitivity of 94.4% (17/18) and specificity of 96.3% (52/54) for distinguishing dysplasia from normal gastric tissue in vivo.

Raman spectra of normal and precancer gastric tissue using PCA-LDA together with the leave-one tissue site-out, cross-validation techniques. The PCA-LDA algorithm based on in vivo gastric Raman spectra provides a diagnostic sensitivity of 94.4% (17/18) and specificity of 96.3% (52/54) for distinguishing dysplasia from normal gastric tissue in vivo. To further evaluate the performance of the PCA-LDA-based diagnostic algorithms derived from all three significant PCs of in vivo gastric Raman datasets, the receiver operating characteristic (ROC) curve (Fig. 4) is also generated from the scatter plot in Fig. 3 at different threshold levels, displaying the discrimination results using PCA-LDA diagnostic algorithms together with the leave-one tissue site-out, cross-validation method. The integration area under the ROC curve is 0.997, further demonstrating the diagnostic efficacy of Raman endoscopy for in vivo diagnosis of gastric precancer during clinical gastroscopic examination.

In summary, we have acquired, for the first time, high-quality in vivo Raman spectra from normal and dysplastic gastric tissue within 0.5 sec under narrow-band imaging guidance during clinical gastroscopy. We have observed the significant differences in in vivo Raman spectra between normal and dysplastic gastric tissue. Good differentiation between normal and dysplastic gastric tissues can be achieved using PCA-LDA diagnostic algorithms, indicating the potential of Raman endoscopy for in vivo diagnosis of gastric precancer. Currently, we are conducting in vivo Raman measurements on a larger series of gastric patients at National University Hospital, Singapore, to further evaluate the clinical merits of Raman endoscopy techniques for prospective prediction of gastric precancer and early cancer in vivo during gastroscopic examination.

Acknowledgments
This research was supported by the National Medical Research Council, the Biomedical Research Council, and the Faculty Research Fund from the National University of Singapore.

References